Horvath Dennis, Basler Michael
Division of Immunology, Department of Biology, University of Konstanz, D-78457 Konstanz, Germany.
Centre for the Advanced Study of Collective Behaviour, University of Konstanz, D-78457 Konstanz, Germany.
Pharmaceutics. 2023 Feb 11;15(2):615. doi: 10.3390/pharmaceutics15020615.
Poly(lactic-co-glycolic acid) (PLGA) particles are a widely used and extensively studied drug delivery system. The favorable properties of PLGA such as good bioavailability, controlled release, and an excellent safety profile due to the biodegradable polymer backbone qualified PLGA particles for approval by the authorities for the application as a drug delivery platform in humas. In recent years, immunotherapy has been established as a potent treatment option for a variety of diseases. However, immunomodulating drugs rely on targeted delivery to specific immune cell subsets and are often rapidly eliminated from the system. Loading of PLGA particles with drugs for immunotherapy can protect the therapeutic compounds from premature degradation, direct the drug delivery to specific tissues or cells, and ensure sustained and controlled drug release. These properties present PLGA particles as an ideal platform for immunotherapy. Here, we review recent advances of particulate PLGA delivery systems in the application for immunotherapy in the fields of allergy, autoimmunity, infectious diseases, and cancer.
聚乳酸-羟基乙酸共聚物（PLGA）颗粒是一种广泛应用且深入研究的药物递送系统。PLGA具有良好的生物利用度、控释特性以及因其可生物降解的聚合物主链而具备出色的安全性等有利特性，这使得PLGA颗粒获得了相关部门的批准，可作为人体药物递送平台应用。近年来，免疫疗法已成为多种疾病的有效治疗选择。然而，免疫调节药物依赖于靶向递送至特定免疫细胞亚群，且常常会迅速从系统中清除。将用于免疫疗法的药物负载到PLGA颗粒中，可以保护治疗性化合物免于过早降解，将药物递送至特定组织或细胞，并确保药物的持续和控释。这些特性使PLGA颗粒成为免疫疗法的理想平台。在此，我们综述了颗粒状PLGA递送系统在过敏、自身免疫性疾病、传染病和癌症等领域免疫疗法应用中的最新进展。
